Mortality trends for cervical squamous and adenocarcinoma in the United States
暂无分享,去创建一个
[1] M. Quinn,et al. Microinvasive Adenocarcinoma of the Cervix: A Clinicopathologic Study of 77 Women , 1997, Obstetrics and gynecology.
[2] S. Granter,et al. Papanicolaou smear sensitivity for adenocarcinoma in situ of the cervix. A study of 34 cases. , 1997, American journal of clinical pathology.
[3] David R. Scott,et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. , 2003, Journal of the National Cancer Institute.
[4] H. Sung,et al. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. , 2003, Obstetrics and gynecology.
[5] S. Granter,et al. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix , 2001, Cancer.
[6] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[7] C. Wheeler,et al. Risk factors for rapid-onset cervical cancer. , 1999, American journal of obstetrics and gynecology.
[8] P. Porter,et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[9] C. Woodman,et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia , 2003, The Lancet.
[10] M. Saville,et al. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening , 2003, Cancer.
[11] S. Saltzstein,et al. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. , 1999, Gynecologic oncology.
[12] T. Reynolds. States begin CDC-sponsored breast and cervical cancer screening. , 1992, Journal of the National Cancer Institute.
[13] E. Feuer,et al. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. , 1994, Journal of clinical epidemiology.
[14] G. Chêne,et al. Survival and prognosis of women with invasive cervical cancer according to age. , 2003, Gynecologic oncology.
[15] F. X. Bosch,et al. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.
[16] Mark Sherman,et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.
[17] P. Boyle,et al. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. , 1996, International journal of epidemiology.
[18] M. Schiffman,et al. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. , 2003, Journal of the National Cancer Institute. Monographs.
[19] V. Václavinková. Behavior of Moderate Cervical Dysplasia During Long-Term Follow-Up , 1983, Obstetrics and gynecology.
[20] J. Fiorica. The role of topotecan in the treatment of advanced cervical cancer. , 2003, Gynecologic oncology.
[21] M. Sherman,et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000 , 2004, Cancer.
[22] G. Giles,et al. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. , 1995, British Journal of Cancer.
[23] M. Sherman,et al. Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[24] V. Moreno,et al. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas , 1998, International journal of cancer.
[25] G. Friedell,et al. Adenocarcinoma in situ of the endocervix , 1953, Cancer.
[26] C. Key,et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. , 2000, Gynecologic oncology.
[27] Evan R. Myers,et al. Accuracy of the Papanicolaou Test in Screening for and Follow‐up of Cervical Cytologic Abnormalities: A Systematic Review , 2001 .
[28] P. Trott,et al. International Classification of Diseases for Oncology , 1977 .
[29] Diane Solomon,et al. The Bethesda System for Reporting Cervical Cytology , 2004 .
[30] H. 0. Smith,et al. Adenocarcinoma in situ of the cervix: Sensitivity of detection by cervical smear , 2002, Cancer.
[31] L. Becker,et al. Are fluid-based cytologies superior to the conventional Papanicolaou test? A systematic review. , 2001, The Journal of family practice.
[32] A. Raffle,et al. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented , 2003, BMJ : British Medical Journal.